Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A pre-results look ahead of Pfizer’s third-quarter results points to oncology drug sales, the growing role of biosimilars, and progress across late-stage pipeline programs as the main factors that could shape sentiment.
THE APEX TIMES
THE APEX TIMES
Even as GlaxoSmithKline moves a competing mRNA-based influenza program into Phase III, traders sent Moderna higher, suggesting investors are weighing platform validation and timing more than near-term competitive risk.
THE APEX TIMES
A new report highlighted clinical research around Zepbound, a weight-loss medicine linked to Eli Lilly, arguing the findings could matter to investor sentiment, even as key trial details were not provided in the post.
THE APEX TIMES
JNJ closed at $271.19 on Sept. 1, up 2.01% from the prior session, according to Yahoo Finance market data.
THE APEX TIMES
A fresh jury finding in a Louisiana talc-related mesothelioma case underscores how Johnson & Johnson (JNJ) remains exposed to trial-by-trial outcomes in its long-running litigation over alleged asbestos contamination in talc products.
THE APEX TIMES
Market commentary tied recent gains in Salior Therapeutics (SLS) and ImmunityBio (IBRX) to a renewed perception that Big Pharma is willing to pay premium prices for immune-focused platforms, pointing to Eli Lilly’s latest reported deal value.
THE APEX TIMES
Moderna’s stock logged its strongest monthly gain in August after market attention concentrated on favorable trial results for one of its pipeline therapies.
THE APEX TIMES
Eli Lilly says a milestone-based immunology deal that adds a broader scientific platform has begun a Phase 1 study, but its lead medicine is still at the earliest clinical stage, underscoring the execution risk common to early-stage pipeline builds.
THE APEX TIMES
The U.S. drugmaker said it will acquire Merida Biosciences in a transaction valued at $2.88 billion, a move that is drawing attention to how Lilly is expanding its pipeline and capabilities.
